{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:23:10Z","timestamp":1778678590802,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.neo.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T13:00:22Z","timestamp":1560517222000},"page":"731-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+\/\u2212 Mice"],"prefix":"10.1016","volume":"21","author":[{"given":"Ashley T.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalin","family":"Narov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth P","family":"Henske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neo.2019.05.003_bb0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"Consortium","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.neo.2019.05.003_bb0010","first-page":"1201","article-title":"Henske EP tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features","volume":"149","author":"Bjornsson","year":"1996","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.neo.2019.05.003_bb0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","article-title":"Renal cell carcinoma in tuberous sclerosis complex","volume":"38","author":"Yang","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.neo.2019.05.003_bb0020","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","article-title":"Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients","volume":"38","author":"Guo","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"10.1016\/j.neo.2019.05.003_bb0025","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","article-title":"A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma","volume":"14","author":"Wilson","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.neo.2019.05.003_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","article-title":"Tsc2(+\/\u2212) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background","volume":"104","author":"Onda","year":"1999","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.neo.2019.05.003_bb0035","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/onc.2014.17","article-title":"Renal tumours in a Tsc2(+\/\u2212) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin","volume":"34","author":"Yang","year":"2015","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.neo.2019.05.003_bb0040","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.ejrad.2011.06.054","article-title":"T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis","volume":"81","author":"Kalogerou","year":"2012","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.neo.2019.05.003_bb0045","first-page":"1639","article-title":"Yeung RS Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors","volume":"151","author":"Henske","year":"1997","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.neo.2019.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","article-title":"A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex","volume":"24","author":"Tyburczy","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neo.2019.05.003_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.neo.2019.05.003_bb0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.neo.2019.05.003_bb0065","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.neo.2019.05.003_bb0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neo.2019.05.003_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.neo.2019.05.003_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40291-016-0192-5","article-title":"Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy","volume":"20","author":"Piva","year":"2016","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"10.1016\/j.neo.2019.05.003_bb0090","first-page":"1765","article-title":"Tuberin regulates E-cadherin localization","volume":"177","author":"Barnes","year":"2010","journal-title":"implications in epithelial-mesenchymal transition Am J Pathol"},{"issue":"1","key":"10.1016\/j.neo.2019.05.003_bb0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/ol.2017.6272","article-title":"Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: a preliminary case-control study","volume":"14","author":"Bi","year":"2017","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neo.2019.05.003_bb0105","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9869","key":"10.1016\/j.neo.2019.05.003_bb0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.neo.2019.05.003_bb0115","article-title":"The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex- a case report","volume":"8","author":"Kim","year":"2014","journal-title":"J Med Case Reports"},{"issue":"3","key":"10.1016\/j.neo.2019.05.003_bb0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2019.05.003_bb0125","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","article-title":"Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014","volume":"23","author":"Pike","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.neo.2019.05.003_bb0130","first-page":"125","article-title":"Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma","volume":"5","author":"Liao","year":"2014","journal-title":"Am J Cancer Res"},{"issue":"11","key":"10.1016\/j.neo.2019.05.003_bb0135","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","article-title":"AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules","volume":"14","author":"Guichard","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0140","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.canlet.2014.11.012","article-title":"Pre-clinical evaluation of AZD-2014, a novel mTORC1\/2 dual inhibitor, against renal cell carcinoma","volume":"357","author":"Zheng","year":"2015","journal-title":"Cancer Lett"},{"issue":"35","key":"10.1016\/j.neo.2019.05.003_bb0145","doi-asserted-by":"crossref","first-page":"58504","DOI":"10.18632\/oncotarget.17215","article-title":"The dual PI3KmTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+\u2212 mice through suppression of cell proliferation and induction of apoptosis","volume":"8","author":"Narov","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032043","article-title":"System-wide immunohistochemical analysis of protein co-localization","volume":"7","author":"Kim","year":"2012","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9440(10)63843-6","article-title":"Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures","volume":"162","author":"Karbowniczek","year":"2003","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.neo.2019.05.003_bb0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40291-016-0192-5","article-title":"Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy","volume":"20","author":"Piva","year":"2016","journal-title":"Mol Diagn Ther"},{"issue":"37","key":"10.1016\/j.neo.2019.05.003_bb0165","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1073\/pnas.1309110110","article-title":"Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis","volume":"110","author":"Gu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.neo.2019.05.003_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.neo.2019.05.003_bb0175","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-14-2535","article-title":"Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival","volume":"75","author":"Schliekelman","year":"2015","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.neo.2019.05.003_bb0180","doi-asserted-by":"crossref","first-page":"27067","DOI":"10.18632\/oncotarget.8166","article-title":"Stability of the hybrid epithelialmesenchymal phenotype","volume":"7","author":"Jolly","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.neo.2019.05.003_bb0185","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/bjc.2011.405","article-title":"Detection of circulating tumour cells with a hybrid (epithelial\/mesenchymal) phenotype in patients with metastatic non\u2013small cell lung cancer","volume":"105","author":"Lecharpentier","year":"2011","journal-title":"Br J Cancer"},{"issue":"6119","key":"10.1016\/j.neo.2019.05.003_bb0190","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"issue":"7568","key":"10.1016\/j.neo.2019.05.003_bb0195","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature14897","article-title":"Distinct EMT programs control normal mammary stem cells and tumour-initiating cells","volume":"525","author":"Ye","year":"2015","journal-title":"Nature"},{"issue":"7579","key":"10.1016\/j.neo.2019.05.003_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"issue":"7579","key":"10.1016\/j.neo.2019.05.003_bb0205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neo.2019.05.003_bb0210","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","article-title":"Lymphangioleiomyomatosis \u2014 a wolf in sheep's clothing","volume":"122","author":"Henske","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neo.2019.05.003_bb0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1476-4598-8-38","article-title":"Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis","volume":"8","author":"Pollizzi","year":"2009","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.neo.2019.05.003_bb0220","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.2016.25","article-title":"Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors","volume":"114","author":"Vandamme","year":"2016","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.neo.2019.05.003_bb0225","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/annonc\/mdw669","article-title":"Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1\/2 inhibition","volume":"28","author":"Kim","year":"2017","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"1","key":"10.1016\/j.neo.2019.05.003_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells","volume":"16","author":"Kahn","year":"2014","journal-title":"Neuro Oncol"},{"issue":"15","key":"10.1016\/j.neo.2019.05.003_bb0235","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","article-title":"First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1\/2 inhibitor AZD2014","volume":"21","author":"Basu","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.neo.2019.05.003_bb0240","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","article-title":"A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer","volume":"69","author":"Powles","year":"2015","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.neo.2019.05.003_bb0245","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-15-0509","article-title":"Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC","volume":"75","author":"Singleton","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.neo.2019.05.003_bb0250","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.molonc.2015.04.016","article-title":"Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells","volume":"9","author":"Catalano","year":"2015","journal-title":"Mol Oncol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558619301484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558619301484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:05:34Z","timestamp":1761483934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558619301484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1476558619301484"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2019.05.003","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+\/\u2212 Mice","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}